Chronic diseases, such as diabetes, cardiovascular conditions, autoimmune disorders, and cancer, represent an escalating global health challenge, exerting ...

As regulators push to phase out animal testing, Charles River’s Steve Bulera notes that widespread implementation of ...

Alpha1H shows benefit in non-muscle invasive bladder cancer, shrinking tumors and boosting the immune system with manageable ...

First-time disclosures session at ACS Fall 2025 reveals diverse candidates for treating sickle cell disease, heart failure, ...

Akeso enrolls first patient in pivotal phase III trial of cadonilimab for perioperative treatment of resectable gastric cancer: Hong Kong Friday, August 22, 2025, 18:00 Hrs [IST] ...

Tryptamine Therapeutics has struck an exclusive deal with world-leading psychedelic researchers Professor Robin ...

Evidence tells us that a treatable traits intervention will improve quality of life for people with chronic obstructive ...

UCLA’s cancer research has been deeply impactful, with millions of people receiving drugs and therapies developed in Bruin ...

A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy ...

In this episode presented by Cresset, BioSpace’s head of insights Lori Ellis discusses clinical trial fail rates and AI’s ...

Strategic leadership appointment strengthens company’s commercial approach to drive continued growth and deliver long-term value ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for atumelnant, a novel, once-daily oral ...